Cargando…

Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis

BACKGROUND: A wide range of rare diseases can have fiscal impacts on government finances that extend beyond expected healthcare costs. Conditions preventing people from achieving national lifetime work averages will influence lifetime taxes paid and increase the likelihood of dependence on public in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connolly, Mark P., Panda, Saswat, Patris, Julien, Hazenberg, Bouke P. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751602/ https://www.ncbi.nlm.nih.gov/pubmed/31533773 http://dx.doi.org/10.1186/s13023-019-1199-x

Ejemplares similares

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
por: Benson, M D, et al.
Publicado: (2020)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

Modified Technique of Ex-PRESS(®) Filtration Device Combined with a Scleral Pocket for Hereditary Transthyretin Amyloidosis (hATTR) Secondary Open-Angle Glaucoma
por: Vieira, Rita, et al.
Publicado: (2023)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese
por: Hsu, Hui-Ching, et al.
Publicado: (2017)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers
por: Luigetti, Marco, et al.
Publicado: (2020)

Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective
por: Connolly, Mark P., et al.
Publicado: (2019)

Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S)
por: Nakase, Taku, et al.
Publicado: (2019)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis
por: Schmidt, Matthias, et al.
Publicado: (2019)

Late-onset Hereditary ATTR Amyloidosis with a Novel p.P63S (P43S) Transthyretin Variant
por: Aono, Yuya, et al.
Publicado: (2020)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

Allele Specific Expression of the Transthyretin Gene in Swedish Patients with Hereditary Transthyretin Amyloidosis (ATTR V30M) Is Similar between the Two Alleles
por: Norgren, Nina, et al.
Publicado: (2012)

Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
por: Jonker, Daphne L., et al.
Publicado: (2018)

Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review
por: Aldinc, Emre, et al.
Publicado: (2023)

In Vivo Quantification of Myocardial Amyloid Deposits in Patients with Suspected Transthyretin-Related Amyloidosis (ATTR)
por: Wollenweber, Tim, et al.
Publicado: (2020)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis
por: Lobato, Luisa
Publicado: (2015)

Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots
por: Auer-Grumbach, Michaela, et al.
Publicado: (2020)

Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
por: Matsushima, Masaaki, et al.
Publicado: (2022)

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
por: Rintell, David, et al.
Publicado: (2021)

Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis
por: Ihse, Elisabet, et al.
Publicado: (2010)

Positron Emission Tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
por: Pilebro, Björn, et al.
Publicado: (2015)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Screening for hereditary transthyretin amyloidosis in Bulgaria
por: Nakov, Radislav, et al.
Publicado: (2021)

Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses
por: Adams, David, et al.
Publicado: (2015)

Bone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool?
por: Duran, Jessica M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hp5n4mfuo2qc2noa99i9tap6mj